Results 61 to 70 of about 181,578 (308)

Improved induction of anti-melanoma T cells by adenovirus-5/3 fiber modification to target human DCs [PDF]

, 2018
To mount a strong anti-tumor immune response, non T cell inflamed (cold) tumors may require combination treatment encompassing vaccine strategies preceding checkpoint inhibition.
Chondronasiou, Dafni, Curiel, David T, de Gruijl, Tanja D, Dmitriev, Igor, Eisden, Tracy-Jane T. H. D, Hooijberg, Erik, Icyuz, Mert, Matthews, Qiana L, Stam, Anita G.M, van de Ven, Rieneke   +9 more
core   +3 more sources

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Tumor site-directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors

Nature Communications
The efficacy of Chimeric Antigen Receptor T cells against solid tumors is limited by immunosuppressive factors in the tumor microenvironment including adenosine, which suppresses Chimeric Antigen Receptor T cells through activation of the A2A receptor ...
Kevin Sek, Amanda X. Y. Chen, Thomas Cole, Jesse D. Armitage, Junming Tong, Kah Min Yap, Isabelle Munoz, Phoebe A. Dunbar, Shiyi Wu, Marit J. van Elsas, Olivia Hidajat, Christina Scheffler, Lauren Giuffrida, Melissa A. Henderson, Deborah Meyran, Fernando Souza-Fonseca-Guimaraes, Dat Nguyen, Yu-Kuan Huang, Maria N. de Menezes, Emily B. Derrick, Cheok Weng Chan, Kirsten L. Todd, Jack D. Chan, Jasmine Li, Junyun Lai, Emma V. Petley, Sherly Mardiana, Anthony Bosco, Jason Waithman, Ian A. Parish, Christina Mølck, Gregory D. Stewart, Lev Kats, Imran G. House, Phillip K. Darcy, Paul A. Beavis   +35 more
doaj   +1 more source

Chimeric antigen receptor T-cell therapy.

Australian prescriber, 2023
Chimeric antigen receptor T-cell therapies are promising new options for patients with relapsed or refractory diffuse large B-cell lymphoma or acute lymphoblastic leukaemia. They increase complete response rates and the chances of achieving prolonged remission.
Burge, Cale, Vanguru, Vinay, Ho, Phoebe Joy   +2 more
openaire   +2 more sources

Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity

Signal Transduction and Targeted Therapy, 2023
Ligand-induced receptor dimerization or oligomerization is a widespread mechanism for ensuring communication specificity, safeguarding receptor activation, and facilitating amplification of signal transduction across the cellular membrane.
Yan Sun, Xiu-Na Yang, Shuang-Shuang Yang, Yi-Zhu Lyu, Bing Zhang, Kai-Wen Liu, Na Li, Jia-Chen Cui, Guang-Xiang Huang, Cheng-Lin Liu, Jie Xu, Jian-Qing Mi, Zhu Chen, Xiao-Hu Fan, Sai-Juan Chen, Shuo Chen   +15 more
doaj   +1 more source

Research Progress of Multi-target CAR-T Cell Therapy for Cancer

Zhongliu Fangzhi Yanjiu, 2022
Chimeric antigen receptor T cell (CAR-T) is a kind of adoptive cell immunotherapy, in which T cells are genetically modified to exert targeted killing effect on tumors.
JIANG Yao, WEN Weihong, YANG Fa, NIE Disen, ZHANG Wuhe, QIN Weijun   +5 more
doaj   +1 more source

Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy. [PDF]

, 2018
Malignant gliomas carry a dismal prognosis. Conventional treatment using chemo- and radiotherapy has limited efficacy with adverse events. Therapy with genetically engineered T-cells, such as chimeric antigen receptor (CAR) T-cells, may represent a ...
Almeida, Neil D, Chuntova, Pavlina, Downey, Kira M, Hegde, Bindu, Okada, Hideho   +4 more
core  

Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer. [PDF]

, 2017
INTRODUCTION: Colorectal cancer remains the second leading cause of cancer death in the United States, and new strategies to prevent, detect, and treat the disease are needed.
Aka, Allison A., Pattison, Amanda M., Rappaport, Jeff A., Sato, Takami, Snook, Adam E., Waldman, Scott A.   +5 more
core   +2 more sources

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Antibody-conjugated lipid nanoparticles for in vivo CAR-T cell engineering: From concept to clinical translation

Nano Biomedicine and Engineering
Chimeric antigen receptor T cell therapy represents a transformative advancement in immunotherapy, wherein engineered T cells target tumor antigens, achieving high response rates in hematological malignancies.
Zhitong Guo, Mengjie Zhang, Yuanyu Huang
doaj   +1 more source